Page last updated: 2024-09-04

edotreotide and Neoplasms

edotreotide has been researched along with Neoplasms in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (16.67)18.2507
2000's13 (72.22)29.6817
2010's0 (0.00)24.3611
2020's2 (11.11)2.80

Authors

AuthorsStudies
Cortés Romera, M; Guerrero-Pérez, F; Herrera-Martínez, Y; Martín-Marcuartu, JJ; Telué Vega, A; Vercher-Conejero, JL1
Antoch, G; Bruckmann, NM; Herrmann, K; Ingenwerth, M; Kirchner, J; Lahner, H; Rischpler, C; Sawicki, LM; Theurer, S; Umutlu, L1
Abolmaali, ND; Abramyuk, AM; Tokalov, SV; Zophel, K1
Besse, IM; Bushnell, DL; Juweid, ME; Madsen, MT1
Endo, K; Hanaoka, H; Higuchi, T; Iida, Y; Oriuchi, N; Paudyal, B; Paudyal, P; Tominaga, H; Watanabe, S; Yamada, K1
Hughey, BJ; Klinkowstein, RE; Laforest, R; Lewis, MR; Margenau, WH; Reichert, DE; Shefer, RE; Welch, MJ1
Bartolomei, M; Bodei, L; Caracciolo, M; Chinol, M; Cremonesi, M; Grana, C; Mäcke, HR; Paganelli, G; Rocca, P; Zoboli, S1
Anderson, T; Atcher, R; Nayak, T; Norenberg, J1
Ginj, M; Hinni, K; Maecke, HR; Schulz, S; Tschumi, S1
Albert, R; Bruns, C; Knecht, H; Pless, J; Simeon, C; Smith-Jones, P; Stolz, B1
Behe, M; Heppeler, A; Herrmann, R; Jermann, E; Maecke, HR; Muller, J; Otte, A; Powell, P1
Chinol, M; Cremonesi, M; Mäcke, HR; Paganelli, G; Zoboli, S1
Bakker, W; Chen, T; Jamar, F; Krenning, E; Kvols, L; Liu, J; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Yeh, CM1
de Jong, M; Krenning, EP; Kwekkeboom, D1
Bartolomei, M; Chinol, M; Cremonesi, M; Ferrari, M; Fiorenza, M; Paganelli, G; Sacco, E; Stabin, MG; Tosi, G1
Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; de Braud, F; De Cicco, C; Ferrari, M; Grana, C; Mäcke, HR; Orsi, F; Paganelli, G; Zoboli, S1
Arnold, R; Becker, W; Béhé, M; Behr, TM; Goldenberg, DM; Gotthardt, M; Gratz, S; Kluge, G; Schipper, ML1
Bodei, L; Chinol, M; Cremonesi, M; Paganelli, G1

Reviews

2 review(s) available for edotreotide and Neoplasms

ArticleYear
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
    Digestion, 2000, Volume: 62 Suppl 1

    Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Dose-Response Relationship, Radiation; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes

2000
Peptide receptor imaging and therapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:10

    Topics: Humans; Indium Radioisotopes; Neoplasms; Neuroendocrine Tumors; Octreotide; Oligopeptides; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes

2000

Trials

4 trial(s) available for edotreotide and Neoplasms

ArticleYear
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:2

    Topics: Adult; Aged; Amino Acids; Biomarkers, Tumor; Blood Platelets; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hemoglobins; Humans; Kidney; Lymphocytes; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Octreotide; Radiation-Protective Agents; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Renal Insufficiency; Vomiting; Yttrium Radioisotopes

2003
Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
    Cancer biotherapy & radiopharmaceuticals, 1999, Volume: 14, Issue:6

    Topics: Adult; Aged; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes

1999
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
    European journal of nuclear medicine, 2001, Volume: 28, Issue:4

    Topics: Adult; Aged; Female; Humans; Indicators and Reagents; Male; Middle Aged; Neoplasms; Octreotide; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tissue Distribution; Tomography, X-Ray Computed; Yttrium Radioisotopes

2001
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group.
    Seminars in nuclear medicine, 2002, Volume: 32, Issue:2

    Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes

2002

Other Studies

12 other study(ies) available for edotreotide and Neoplasms

ArticleYear
[
    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 2023, Volume: 30, Issue:4

    Topics: Gallium Radioisotopes; Humans; Neoplasms; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals

2023
Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naive neuroendocrine neoplasms using hybrid
    European journal of radiology, 2021, Volume: 137

    Topics: Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Multimodal Imaging; Neoplasm Grading; Neoplasms; Octreotide; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals

2021
Retrospective analysis of radiation load during examination of cancer patients by (68)Ga-DOTATOC and (18)F-FDG positron emission tomography.
    Bulletin of experimental biology and medicine, 2008, Volume: 145, Issue:5

    Topics: Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gadolinium; Humans; Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed

2008
Modeling combined radiopharmaceutical therapy: a linear optimization framework.
    Technology in cancer research & treatment, 2009, Volume: 8, Issue:1

    Topics: 3-Iodobenzylguanidine; Humans; Models, Theoretical; Neoplasms; Octreotide; Radiation Dosage; Radiopharmaceuticals

2009
Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
    Annals of nuclear medicine, 2009, Volume: 23, Issue:6

    Topics: Animals; Cell Line, Tumor; Copper Radioisotopes; Gene Expression Regulation, Neoplastic; Humans; Isotope Labeling; Mice; Neoplasms; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Receptors, Somatostatin; Tissue Distribution

2009
Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals.
    Nuclear medicine and biology, 2002, Volume: 29, Issue:6

    Topics: Biotin; Gallium Radioisotopes; Humans; Isotope Labeling; Neoplasms; Octreotide; Organometallic Compounds; Radionuclide Imaging; Radiopharmaceuticals; Zinc Isotopes

2002
A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
    Cancer biotherapy & radiopharmaceuticals, 2005, Volume: 20, Issue:1

    Topics: Actinium; Alpha Particles; Apoptosis; Beta Particles; Bismuth; Cell Line, Tumor; Cell Nucleus; Cell Survival; Dose-Response Relationship, Radiation; Energy Transfer; Enzyme-Linked Immunosorbent Assay; Humans; Ligands; Lutetium; Mitosis; Models, Statistical; Neoplasms; Octreotide; Radioisotopes; Radiometry; Radiopharmaceuticals; Receptors, Somatostatin

2005
Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:12

    Topics: Cell Line; Cell Nucleus; Electrons; Humans; Indium Radioisotopes; Kinetics; Neoplasms; Octreotide; Peptides; Protein Structure, Tertiary; Radioisotopes; Radiotherapy; Receptors, G-Protein-Coupled; Somatostatin; Time Factors; Transfection

2005
Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man.
    Bioorganic & medicinal chemistry letters, 1998, May-19, Volume: 8, Issue:10

    Topics: Drug Carriers; Heterocyclic Compounds, 1-Ring; Humans; Indicators and Reagents; Iodine Radioisotopes; Neoplasms; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes

1998
Yttrium-90 DOTATOC: first clinical results.
    European journal of nuclear medicine, 1999, Volume: 26, Issue:11

    Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neoplasms; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes

1999
Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience.
    The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2000, Volume: 44, Issue:4

    Topics: Humans; Indium Radioisotopes; Neoplasms; Octreotide; Radioimmunotherapy; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes

2000
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.
    European journal of nuclear medicine and molecular imaging, 2002, Volume: 29, Issue:2

    Topics: Animals; Humans; Kidney; Neoplasms; Octreotide; Peptides; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes

2002